Webinar Details:
- Date & Time: On-Demand
- Title: Opioid Use Disorder in Dental Patients
- Cost: $40 for FDA Members | $60 for Non-FDA Members
- Speaker: Jason Portnof, DMD, MD
- Course Description:
The opioid crisis is a public health emergency in the U.S., with a severe impact in Florida. In this webinar, Dr. Portnof will review the current standards for prescribing controlled substances and Florida laws and rules related to the prescribing of controlled substances. Attendees will leave the course able to define acute and chronic pain and opioid addiction and know when to consider non-opioid and non-pharmacological alternatives for treating pain. This lecture satisfies the Florida Board of Dentistry’s mandatory continuing education requirement for Safe and Effective Prescribing of Controlled Substances. These 2 hours of CE can also be used toward the 8-hour MATE Act requirement.
- At the conclusion of this webinar, attendees will be able to:
- Understand the scope of the opioid program and the current situation in Florida.
- Learn the best practices for safe prescribing controlled substances, including emergency opioid antagonists, and monitoring patients.
- Identify the risk of addiction and the best practices for safe and effective treatment of acute paid with opioids.
- Review Florida Laws and Rules related to the prescribing of controlled substances and Florida’s PDMP (E-FORCSE) and instructions regarding usage, with emphasis placed on the recent modifications made to improve safety.
- Discuss the non-opioid and non-pharmacological alternatives for treating pain.
- Speaker: Jason Portnof, DMD, MD
Dental degree, Nova Southeastern University College of Dental Medicine; medical degree, from Weill Cornell Medical College; diplomate, the American Board of Oral and Maxillofacial Surgery; fellow, American College of Surgeons; fellowship training in pediatric maxillofacial surgery/craniomaxillofacial surgery, Royal Children’s Hospital in Melbourne, Australia; private practice, Boca Raton, FL. - Conflict of Interest Disclosure: None Reported

